New X-ray Therapy Spares Rectal Cancer Patients Stoma

A groundbreaking low-energy X-ray treatment for rectal cancer, known as Papillon, has recently gained approval for use within the National Health Service. This innovative therapy provides a viable non-surgical option for patients, potentially eliminating the necessity of a stoma, which significantly enhances their quality of life.

The Papillon treatment involves inserting an X-ray tube through the anus to deliver precise radiation doses directly to cancerous tumours. It is specifically recommended for patients with rectal tumours measuring 3cm or smaller, or those who choose to avoid surgery due to high risk. Pioneers of the technique, like Professor Sun Myint, have been using it for over three decades, with trials demonstrating remarkable success in preserving organs.

This NHS approval is hailed as a major victory for patient choice and well-being. Beyond improving individual lives, the widespread adoption of Papillon is expected to reduce surgical waiting lists and healthcare costs. Colorectal cancer, a common malignancy in the UK, will now benefit from this advanced treatment option, offering hope and better outcomes to many.